Zanamivir in the treatment of influenza

Expert Opinion on Pharmacotherapy

Volumn 4, Issue 5, 2003, Pages 799-805

  Fleming, Douglas ^a  

^a ROYAL COLLEGE OF GENERAL PRACTITIONERS   (United Kingdom)

Author keywords

Influenza; Neuraminidase inhibitors; Prescribing policy; Treatment

Indexed keywords

AMANTADINE; CREATININE; INFLUENZA VACCINE; OSELTAMIVIR; RIMANTADINE; ZANAMIVIR;

ABSENTEEISM; AGE DISTRIBUTION; BRONCHOSPASM; CHRONIC DISEASE; CLINICAL TRIAL; CREATININE CLEARANCE; DIABETES MELLITUS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG COST; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MARKETING; DRUG MECHANISM; EXPERIMENTAL INFECTION; HEALTH CARE UTILIZATION; HEART DISEASE; HOSPITAL ADMISSION; HUMAN; IMMUNE DEFICIENCY; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A; MORTALITY; OTITIS MEDIA; RESPIRATORY TRACT DISEASE; REVIEW; RISK ASSESSMENT; UNITED KINGDOM; VIRUS TRANSMISSION; WINTER;

ADULT; ANIMALS; ANTIVIRAL AGENTS; CHILD; CLINICAL TRIALS; ENZYME INHIBITORS; EXPERT TESTIMONY; GUANIDINES; HUMANS; INFLUENZA, HUMAN; NEURAMINIDASE; PYRANS; RISK FACTORS; SIALIC ACIDS; ZANAMIVIR;

EID: 0038107450     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.4.5.799     Document Type: Review

References (48)

1. CALFEE DP, HAYDEN FG: New approaches to influenza chemotherapy. Neuraminidase inhibitors. Drugs (1998) 56:537-553.
2. GUBAREVA LV, KAISER L, HAYDEN FG: Influenza virus neuraminidase inhibitors. Lancet (2000) 355(9206):827-835.
3. MCKIMM-BRESCHKIN JL: Neuraminidase inhibitors for the treatment and prevention of influenza. Expert Opin. Pharmacother. (2002) 3(2):103-112
4. FREUND B, GRAVENSTEIN S, ELLIOTT M, MILLER I: Zanamivir. A review of clinical safety. Drug Safety (1999) 21(4):267-281.
5. ZAMBON MC: Epidemiology and pathogenesis of influenza. J. Antimicrobiol. Chemother. (1999) 44(Suppl. B):3-9.
6. VARGHESE JN, LAVER WG, COLMAN PM: Structure of the influenza virus glycoprotein antigen neuraminidase at 2,9. Å resolution. Nature (1983) 303:35-40.
7. COLMAN PM, VARGHESE JN, LAVER WG: Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature (1983) 303:41-44.
8. VON ITZSTEIN M, WU W-Y, KOK GB et al.: Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature (1983) 363:418-423.
9. MEINDL P, TUPPY H: [2-Deoxy-2, 3-dehydrosialic acids. II. Competitive inhibition of Vibrio cholerae neuraminidase by 2-deoxy-2, 3-dehydro-N-acylneuraminic acids]. Hoppe Seyler's Zeitschrift fur Physiologische Chemie (1969) 350:1088-1092.
10. PALESE P, COMPANS RW. Inhibition of influenza virus replication in tissue culture by 2-deoxy-2, 3-dehydro-N-trifluoro-acetylneuraminic acid (FANA): mechanism of action. J. Gen. Virol. (1976) 33:159-163.
11. CALFEE DP, PENG AW, CASS LM, LOBO M, HAYDEN FG: Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection Antimicrob. Agents Chemother. (1999) 43(7):1616-1620.
12. CASS LM, BROWN J, PICKFORD M et al.: Pharmacoscintigraphic evaluation of lung deposition of inhaled zanamivir in healthy volunteers. Clin. Pharmacokinet. (1999) 36(Suppl. 1):21-31.
13. CASS LM, EFTHYMIOPOULOS C, BYE A: Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. Clin. Pharmacokinet. (1999) 36(Suppl. 1):1-11.
14. BOIVIN G, GOYETTE N, HARDY I, AOKI FY, WAGNER A, TROTTIER S: Rapid antiviral effect of inhaled zanamivir in the treatment of naturally occurring influenza in otherwise healthy adults. J. Infect. Dis. (2000) 181(4):1471-1474.
15. HAYDEN FG, OSTERHAUS AD, TREANOR JJ et al.: Efficacy and safety of neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. N. Engl. J. Med. (1997) 337:874-880.
16. MONTO AS, WEBSTER A, KEENE O: Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: pooled efficacy analysis. J. Antimicrob. Chemother. (1999) 44(Suppl. B):23-29.
17. MURPHY KR, EIVINDSON A, PAUKSEN K et al.: Efficacy and safety of inhaled zanamivir for the treatment of influenza in patients with asthma or chronic obstructive pulmonary disease. Clin. Drug Invest. (2000) 5:337-349.
18. LOUGHLIN JE, ALFREDSON TD, AJENE AN et al.: Risk for respiratory events in a cohort of patients receiving inhaled zanamivir: a retrospective study. Clin. Ther. (2002) 24:1786-1799.
19. WEBSTER A, BOYCE M, EDMUNDSON S, MILLER I: Coadministration of orally inhaled zanamivir with inactivated trivalent influenza vaccine does not adversely affect the production of antihaemagglutinin antibodies in the serum of health volunteers. Clin. Pharmacokinet. (1999) 36(Suppl. 1):51-58.
20. 2 ion channel protein. Sem. Virol. (1992) 3:21-30.
21. GRAVENSTEIN S, DRINKA P, OSTERWEIL et al.: A multi-centcr prospective trial comparing the relative safety and efficacy of zanamivir to rimantadine for nursing home influenza outbreak control. Conference program and abstracts of the options for control of influenza IV. European Scientific Working Group on Influenza 2000. Abstract W22-1.
22. MCKIMM-BRESCHKIN JL: Resistance of influenza viruses to neuraminidase inhibitors - a review. Antivir. Res. (2000) 47:1-17.
23. GUBAREVA LV, MATROSOVICH MN, BRENNER MK, BETHELL RC, WEBSTER RG: Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J. Infect. Dis. (1998) 178:1257-1262.
24. MCCLELLAN K, PERRY CM: Oseltamivir. A review of its use in influenza. Drugs (2001) 61(2):263-283.
25. ZAMBON MC, HAYDEN PG: Review: position statement: global; neuraminidase inhibitor susceptibility network. Antiviral Res. (2001) 49:147-156.
26. WHITELY RJ, HAYDEN FG, REISINGER KS et al.: Oral oseltamivir treatment of influenza in children. Pediatr. Infect. Dis. J. (2001) 20:127-133.
27. WALKER JB, HUSSEY EK, TREANOR JJ, MONTALVO JRA, HAYDEN FG: Effects of the neuraminidase inhibitor zanamivir on otologic manifestations of experimental human influenza. J. Infect. Dis. (1997) 176:1417-1422.
28. HAYDEN FG, TREANOR JJ, BETTS RF et al.: Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. JAMA (1996) 275:295-299.
29. Randomized trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. The Management of influenza in the Southern Hemisphere Trialists (MIST) study group. Lancet (1998) 352:1877-1881.
30. LALEZARI J, CAMPION K, KEENE O, SILAGY C: Zanamivir for the treatment of influenza A and B infection in high risk patients: a pooled analysis of randomised controlled trials. Arch. Intern. Med. (2001) 161(2):212-217.
31. HEDRICK JA, BARZILAI A, BEHRE U et al.: Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial. Pediatr. Infect. Dis. J. (2000) 19:410-417.
32. MAKELA MJ, PAUKSENS K, ROSTILA T et al.: Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomised, double-blind, placebo controlled European study. J. Infection. (2000) 40:42-48.
33. KAISER L, KEENE ON, HAMMOND JM et al.: Impact of zanamivir on antibiotic use for respiratory events following acute influenza in adolescents and adults. Arch. Intern. Med. (2000) 160:3234-3240.
34. JOHNY AA. CLARK A, PRICE N, CARRINGTON D, OAKHILL A, MARKS DI: The use of zanamivir to treat influenza A and B infection after allogeneic stem cell transplantation. Bone Marrow Transplant. (2002) 29:113-115.
35. LEVY E: French economic evaluations of influenza and influenza vaccination. Pharmoeconomics (1996) 9(Suppl. 3):62-66.
36. SZUCS T: The socio-economic burden of influenza. J. Antimicrob. Chemother. (1999) 44(Suppl. B):11-15.
37. SZUCS TD: Influenza: the role of burden of illness research. Pharmoeconomics (1999) 16(Suppl. 1):27-32.
38. DRINKA PJ GRAVENSTEIN S, KRAUSE P, NEST L, DISSING M, SHULT P: Reintroduction of influenza A to a nursing building. Infect. Control Hosp. Epidemiol. (2000) 11:732-735.
39. MONTO AS, PICHICHERO ME, BLANCKENBERG SJ et al.: Zanamivir prophylaxis: an effective strategy for the prevention of influenza types A and B within households. Infect. Dis. (2002) 186(11):1582-1588.
40. LODER N: UK government not convinced by claims for flu drug. Nature (1999) 401(6754):631.
41. HOFFKEN G, GILLISSEN A: Efficacy and safety of zanamivir in patients with influenza - impact of age, severity of infections and specific risk factors. Med. Microbiol. Immunol. (2002) 191:169-173.
42. Guidance to the NHS on zanamivir (Relenza) October 1999. National Institute for Clinical Excellence (1999).
43. HAYDEN FG, COATS T, KIM K et al.: Oral pleconaril treatment of picornavirus-associated viral respiratory illness in adults: efficacy and tolerability in Phase II clinical trials. Antivir. Ther. (2002) 1:53-65.
44. FLEMING DM: The contribution of influenza to combined acute respiratory infections, hospital admissions, and deaths in winter. Commun. Dis. Public Health (2000) 1:32-38.
45. FLEMING DM, ZAMBON M, BARTELDS AI, DE JONG JC: The duration and magnitude of influenza epidemics: a study of surveillance data from sentinel general practices in England, Wales and the Netherlands. Eur. J. Epidemiol. (1999) 5:467-473.
46. GODDARD NL, JOSEPH CA, ZAMBON M, NUNN M, FLEMING D WATSON JM: Influenza surveillance in England and Wales: October 1999 to May 2000. Commun. Dis. Public Health (2000) 3:262-266.
47. ROSS AM, KAI J, SALTER R, ROSS J, FLEMING DM: Presentation with influenza-like illness in general practice: implications for use of neuraminidase inhibitors. Commun. Dis. Public Health (2000) 3:256-260.
48. HAYDEN FG: Perspectives on antiviral use during pandemic influenza 1: Philos. Trans. R. Soc. Lond. B. Biol. Sci. (2001) 356(1416):1877-1884.